Business
Trading Update
Trading Update.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n17 January 2008\n\n\n Update on trading and reporting timetable\n\n\nLONDON, 17 January 2008 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:\nHIK), the multinational pharmaceuticals group, confirms that since the\npublication of its pre-close trading statement on 14 December 2007 there has\nbeen no change to its expectations for the 2007 financial year or its outlook\nfor 2008. Hikma also announces that it will make the preliminary announcement\nof its results for the year ended 31 December 2007 on 18 March 2008, updating\nthe previously advised date of 12 March 2008. Consequently, the corresponding\nclose period will begin on 18 January 2008.\n\n\n - ENDS -\n\nEnquiries:\n\n\nHikma Pharmaceuticals PLC\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\n\nAbout Hikma\n\nHikma Pharmaceuticals PLC is a fast growing multinational group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed products. Hikma operates through three\nbusinesses: 'Branded', 'Injectables' and 'Generics', based principally in the\nMiddle East and North Africa ('MENA'), where it is a market leader and sells\nacross 18 countries, the United States and Europe. In 2006, Hikma achieved\nrevenues of $317 million (2005 $262 million) and profit attributable to\nshareholders was $55 million (2005 $44 million). At 31 December 2006, the Group\nhad over 2,400 employees. For news and other information, please visit\nwww.hikma.com.\n\n\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange \n ","length":2058,"tagName":"div"}]